ABSTRACT In a double-blind placebo-controlled trial in 24 patients fulfilling the MRC criteria for chronic bronchitis, oral salbutamol 4 mg and slow-release aminophylline (Phyllocontin) 
We have now demonstrated similar improvements in 12MD after aerosol2 and oral bronchodilator therapy in patients with chronic bronchitis. In neither study do our results suggest a close correlation between changes in FEV1 and 12MD. This could be related to poor physical fitness in our patients. This would restrict their ability to benefit maximally in terms of exercise tolerance from the acute improvements in airways obstruction produced by the bronchodilator medications. Such a hypothesis is open to testing in chronic bronchitic patients who have been trained.10- 12 We conclude that oral salbutamol and Phyllocontin in conventional dosage improve exercise tolerance in chronic bronchitis. Simultaneous administration of the drugs is not associated with any further improvement in exercise tolerance.
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